BD Bionutrients Technical Manual BD Biosciences – Advanced Bioprocessing

Total Page:16

File Type:pdf, Size:1020Kb

BD Bionutrients Technical Manual BD Biosciences – Advanced Bioprocessing BD Difco™ ™ BD BBL I-452-0160.tif 40 BD Bacto™ BD Bionutrients Technical Manual BD Biosciences – Advanced Bioprocessing Fourth Edition Your Cell Solutions Partner TABLE OF CONTENTS INTRODUCTION .......................................................................1 ANIMAL-ORIGIN PEPTONES .............................................30 Capability ...........................................................................1 Meat Peptones .................................................................30 History ................................................................................2 BD BBL™ Beef Extract Powder....................................30 Product Quality ..................................................................2 BD Bacto™ Beef Extract, Desiccated ...........................30 Service ................................................................................3 BD BBL™ Gelysate™ Peptone......................................32 BD Bacto™ Neopeptone .............................................33 HYDROLYSIS TO HYDROLYSATE .......................................4 BD Bacto™ Peptone ....................................................34 ™ ™ BD BBL Polypeptone Peptone ................................35 Protein Hydrolysis ..............................................................4 ™ BD Bacto Proteose Peptone .....................................36 Peptone Manufacture .........................................................5 ™ BD BiTek Proteose Peptone .....................................37 Ultrafiltration .....................................................................6 ™ BD Bacto Proteose Peptone, No.2 ............................37 ™ BD Bacto Proteose Peptone, No.3 ............................37 ™ CELL CULTURE APPLICATIONS ...........................................7 BD BiTek Proteose Peptone, No.3 ............................37 ™ Introduction .......................................................................7 BD Bacto Proteose Peptone, No.4 ............................37 ™ BD Bacto Tryptose ...................................................40 Base Medium Selection ......................................................8 Casein and Whey Peptones ..............................................44 Supplement and Feed Selection .........................................8 ™ ™ Process Optimization........................................................10 BD BBL Acidicase Peptone ....................................44 BD Bacto™ Casamino Acids........................................45 BD Bacto™ Casamino Acids, Technical ........................45 FERMENTATION APPLICATIONS ......................................14 BD BBL™ Biosate Peptone ..........................................46 Defined vs Complex Media ..............................................14 BD Difco™ Casein Digest ............................................47 Media Design ...................................................................14 BD Bacto™ Casitone ...................................................48 Selecting a Peptone ..........................................................15 BD BBL™ Trypticase™ Peptone ....................................48 Moving to Animal-Free Media Components .....................15 BD Bacto™ Tryptone ...................................................48 BD BiTek™ Tryptone ....................................................48 ANIMAL-FREE PEPTONES AND YEAST EXTRACTS ...17 BD Bacto™ TC Lactalbumin Hydrolysate .....................51 Soy Peptones ....................................................................17 CHEMICALLY DEFINED SUPPLEMENTS AND FEEDS ...54 Yeast Products ..................................................................17 Product Listings ................................................................18 Chemically Defined Supplements .....................................54 BD Bacto™ Malt Extract .............................................18 BD Recharge™ ..................................................................55 BD BBL™ Phytone™ Peptone ......................................19 BD Resurge™ ....................................................................56 BD Difco™ Select Phytone™ UF ..................................19 BD Difco™ Select Soytone ..........................................19 BD Bacto™ Soytone ....................................................20 BD Bacto™ TC Yeastolate ...........................................23 BD Difco™ TC Yeastolate, UF ......................................23 BD Bacto™ Yeast Extract ............................................25 BD BBL™ Yeast Extract ...............................................25 BD Bacto™ Yeast Extract, Technical ............................25 BD Difco™ Yeast Extract, UF .......................................25 bdbiosciences.com/advbio BD Biosciences – Advanced Bioprocessing i TABLE OF CONTENTS BIONUTRIENTS MEDIA .......................................................58 Mammalian Cell Culture Media .......................................58 BD Cell™ mAb Medium, Animal Component Free ......58 BD Cell™ mAb Medium, Quantum Yield .....................58 BD Select™ CHO .........................................................59 BD Select™ CD1000 Medium .....................................60 Microbial Fermentation ....................................................61 BD BBL™ Select APS LB Broth Base ............................61 BD Difco™ Select APS Super Broth .............................. 61 BD Bacto™ Tryptose Phosphate Broth ........................61 BD Difco™ M9 Minimal Salts, 5X ................................ 65 BD Difco™ Yeast Nitrogen Base ..................................66 BD Difco™ Yeast Nitrogen Base, w/o Amino Acids ......66 BD Difco™ Yeast Nitrogen Base w/ Amino Acids and Ammonium Sulfate .............................................66 PROTOCOLS AND DEFINITION OF METHODS ...........68 Supplement Titration and Blending Protocols ...................68 Adaptation Protocols .......................................................71 Definition of Methods ......................................................72 REGULATORY DOCUMENTATION ...................................73 Certificates of Analysis .....................................................73 Change Notification Program ...........................................73 Certificates of Suitability ..................................................73 PRODUCT LISTING ................................................................74 ii BD Bionutrients Technical Manual Fourth Edition INTRODUCTION Introduction The BD Bionutrients Technical Manual is an easy-to-use reference tool to provide guidance in the selection of BD products for use in cell culture and microbial fermentation production, from research and development to the final finished product. It is our commitment to innovation and product consistency that makes BD (Becton, Dickinson and Company) a strong global supplier and partner. Through BD Biosciences – Advanced Bioprocessing (BDAB), we offer a full line of cell culture media, supplements and feeds (bionutrients) for the biotechnology, biopharmaceutical, and animal and human vaccine markets. Our dedication to cell culture and fermentation media markets is exemplified in our wide range of capabilities: • Bioproduction Media and Supplements Manufacturing — As part of BD’s global network of manufacturing centers, BDAB is focused on the development and manufacture of bionutrients. Our full suite of manufacturing services is tailored to meet the needs of your production process—from rapid small-scale medium production to full-scale GMP medium manufacturing. In Sparks, Maryland, our manufacturing plant produces dehydrated culture media (DCM), animal-origin bionutrients, ingredients, stains, and other products for microbiology and cell culture. Our first-of-its-kind, animal-free, antibiotic-free (AF2)™ bionutrients manufacturing facility in Miami, Florida solidifies BD’s commitment to providing high-quality, high-performing animal-free products for the cell culture industry. BDAB bionutrient manufacturing capabilities offer flexibility and capacity without sacrificing quality. Keeping your needs in mind, we are able to customize our processes and testing to meet your requirements, all while adhering to stringent quality standards. • Full Line of Supplements and Feeds for the Biopharmaceutical Market — BDAB has been a pioneer and a trusted partner of leading biopharmaceutical companies around the world. As a result, our products are used in the manufacture of more than 110 animal and human health biopharmaceuticals on the market today. Our offering of animal-free, animal-origin, and chemically defined supplements and feeds are tailored to work in a variety of biopharmaceutical applications to help you achieve optimal production yields with consistent performance. bdbiosciences.com/advbio BD Biosciences – Advanced Bioprocessing 1 INTRODUCTION • Media Design Service — BDAB offers a full of range of services from the development of custom media and feed formulations to the optimization of existing media and feeds. Our experience, combined with our proven methodology and extensive analytical capabilities, allow us to provide customers medium that works with their unique specifications, on time, and within budget. To learn more about BDAB Media Design Services, contact your local BD associate. History Beginning in 1895, Difco Laboratories produced high-quality enzymes, dehydrated tissues, and glandular products to aid in the digestion process.
Recommended publications
  • Genomic and Evolutionary Insights
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Apollo GBE Preterm Infant-Associated Clostridium tertium, Clostridium cadaveris,andClostridium paraputrificum Strains: Genomic and Evolutionary Insights Raymond Kiu1,2, Shabhonam Caim1, Cristina Alcon-Giner1, Gusztav Belteki3,PaulClarke4, Derek Pickard5, Gordon Dougan5,andLindsayJ.Hall1,* 1The Gut Health and Food Safety Programme, Quadram Institute Bioscience, Norwich Research Park, Norwich, United Kingdom 2Norwich Medical School, Norwich Research Park, University of East Anglia, Norwich, United Kingdom 3Neonatal Intensive Care Unit, The Rosie Hospital, Cambridge University Hospitals NHS Foundation Trust, United Kingdom 4Neonatal Intensive Care Unit, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom 5Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom *Corresponding author: E-mail: [email protected]. Accepted: September 28, 2017 Data deposition: This project has been deposited at European Nucleotide Archive (EMBL-EBI) under the accession PRJEB22142. Bacterial strain deposition: Newly sequenced strains are deposited at National Collection of Type Cultures (NCTC; a culture depository of Public Health England). Abstract Clostridium species (particularly Clostridium difficile, Clostridium botulinum, Clostridium tetani and Clostridium perfringens)are associated with a range of human and animal diseases. Several other species including Clostridium tertium, Clostridium cadaveris, and Clostridium paraputrificum have also been linked with sporadic human infections, however there is very limited, or in some cases, no genomic information publicly available. Thus, we isolated one C. tertium strain, one C. cadaveris strain and three C. paraputrificum strains from preterm infants residing within neonatal intensive care units and performed Whole Genome Sequencing (WGS) using Illumina HiSeq. In this report, we announce the open availability of the draft genomes: C.
    [Show full text]
  • Commercial Model of the Future
    BioPharma BD Quarterly Newsletter Q2 2018 Syneos Health Consulting Commercial Strategy & Planning | Portfolio Strategy Solution Center Syneos Health BioPharma BD Quarterly Newsletter | Q2 2018 Q2 FDA Approvals | Q3 PDUFA Dates | Q2 Deal Summary | Q2 Mergers & Acquisitions | Q2 Partnerships | Q2 Asset Purchases Q2 FDA Approvals1,2 In order of 2020 sales forecast No sales listed Aimovig (erenumab) | Novartis / Amgen (co- Akynzeo IV (fosnetupitant) | Helsinn Group commercialize) . Prevention of acute and delayed nausea Migraine, first CGRP receptor blocker associated with cancer chemotherapy . 2020E Sales: $470M Bendamustine HCl Injection (bendamustine AndexXa (andexanet alfa) | Portola hydrochloride) | Spectrum Pharmaceuticals / Pharmaceuticals Eagle Pharmaceuticals (co-promotion Neel Patel . Used for uncontrolled bleeding in patients that agreement) used rivaroxaban and apixaban . Chronic lymphocytic leukemia Managing Director . 2020E Sales: $258M [email protected] Consensi (amlodipine besylate) | Kitov / Dexcel Fulphila (pegfilgrastim) | Mylan / Biocon Pharma Technology (cooperation agreement- (partnership) Dexcel will develop drugs final formulation-Kitov . Decrease incidence of infection, as manifested by pays Dexcel $3.5M for company’s facilities) febrile neutropenia . Amlodipine for hypertension and celecoxib for . 2020E Sales: $244M osteoarthritis Lokelma (sodium zirconium cyclosilicate) | Crysvita (burosumab) | Ultragenyx AstraZeneca / Incyte (clinical trial collaboration) Pharmaceutical . Treatment of hyperkalemia in adults
    [Show full text]
  • Product Brand List November, 2015
    Product Brand List November, 2015 BD™ BD Autoguard-N Pro™ BD CARV II™ BD 6CESS™ BD Autoguard™ BD Cato™ 6mm™ (circle design) BD AutoMagic™ BD CatoPAN™ BD A-Cath™ BD AutoNutrient™ BD Chemocato™ BD Accu-Glass™ BD AutoPap™ BD CDT™ BD Accuri™ BD AutoSceptor™ BD Cefinase™ BD Accuspray™ BD AutoShield™ BD CellFIT™ (EU only) BD Acidicase™ BD AutoShield Duo™ BD CellFIX™ (EU only) BD Activ 8™ BD Ayre Cervi-Scraper™ BD Cellmatics™ BD Activation Assist™ BD BACTEC™ BD CellQuest™ Pro BD ACTOne™ BD BACTEC FX™ BD CellWASH™ (EU only) BD Adams™ BD BACTEC™ MGIT™ BD CFlow™ BD Adsyte™ BACTEC Plus Prime™ (Japan) BD Champion™ BD Affirm™ BD Bacto™ BD Chek™ BD AICE™ BD Bact-Plate™ BD CHG™ BD A-Line™ BD Bactrol™ BD CLIC™ BD Amplatz™ BD Bactrol™ Plus BD CLyse™ BD Angiocath Plus/Pro™ (Asia only) BD BaculoGold™ BD CS Quadcount™ BD Angiocath-N™ Autoguard™ BD Barricor™ BD CSampler™ BD Angiocath™ BD BBLCrystal™ BD CX Sampler™ BD Angiocath™ Autoguard™ BD BBL™ CHROMagar (under license) BD Angio-set™ BD BBL™ Crystal™ BD Clay Adams™ BD Apem™ BD BeAware™ BD Cliniject™ BD Asepta-Cell™ BD Bio-Bag™ BD CloneCyt™ BD Asepto™ BD Biosate™ BD CloneCyt™ Plus BD Assurity Linc™ BD BiTek™ BD CMVscan™ BD Attofluor™ BD Bonnano™ BD ColorPAC™ BD Atto™ BD Busher™ BD Connecta™ BD Attovision™ BD Calibrite™ BD Cornwall™ BD Attractors™ BD Calibrite™ 3 BD CPT™ BD Autocrit™ BD CampyPak™ BD CrystalSpec™ BD Autocyte™ BD CampyPak™ Plus BD Crystal™ BD Autocyte Quic™ BD CampyPouch™ BD Autoguard Pro™ BD Campyslide™ Product Brand List November, 2015 cont'd BD CSI™ BD Easy™ BD FACSLyric™ BD CTA Medium™
    [Show full text]
  • Becton Dickinson 2000 Annual Report
    Becton, Dickinson and Company 2000 Annual Report Tools for human health 2000 Annual Report Becton, Dickinson and Company 1 Becton Drive Franklin Lakes, NJ 07417-1880 http://www.bd.com Becton, Dickinson and Company Corporate Information Board of Directors Contents Harry N. Beaty, M.D.1,4 Albert J. Costello1,6 Frank A. Olson2,5,6 James E. Perrella2,3,5 1 Letter to Shareholders Emeritus Dean–Northwestern Retired Chairman of the Board, Chairman of the Board Retired Chairman of the Board– 5 Tools for Human Health University Medical School, and President and Chief Executive and Retired Chief Executive Ingersoll-Rand Company 16 At a Glance Chairman of the Board and Officer–W.R. Grace & Co. Officer– The Hertz Corporation Alfred Sommer1,3 President–Northwestern Gerald M. Edelman, James F. Orr1,4 Dean of the Johns Hopkins 18 Nine-Year Summary University Medical Faculty M.D., Ph.D.4,5,6 Chairman, President and School of Hygiene and Public 20 Financial Review Foundation Director–The Neurosciences Chief Executive Officer– Health, and Professor of 28 Financial Statements Henry P. Becton, Jr.2,3,4 Institute, Member–The Scripps Convergys Corporation Ophthalmology, Epidemiology 49 Corporate Information: President and General Manager– Research Institute Willard J. Overlock, Jr.2,5,6 and International Health 5 1,4 Board of Directors, WGBH Educational Foundation Edward J. Ludwig Retired Partner–Goldman, Margaretha af Ugglas Clateo Castellini3,5 President and Chief Sachs & Co. Member of the Board– Corporate Officers and From laboratory Chairman of the Board–BD Executive Officer–BD Stockholm University and General Information Jarl Hjalmarson Foundation Committees Appointed by the 1 – Audit Committee to living room, Board of Directors 2 – Compensation and Benefits Committee Corporate Officers Edward J.
    [Show full text]
  • Clostridium Amazonitimonense, Clostridium Me
    ORIGINAL ARTICLE Taxonogenomic description of four new Clostridium species isolated from human gut: ‘Clostridium amazonitimonense’, ‘Clostridium merdae’, ‘Clostridium massilidielmoense’ and ‘Clostridium nigeriense’ M. T. Alou1, S. Ndongo1, L. Frégère1, N. Labas1, C. Andrieu1, M. Richez1, C. Couderc1, J.-P. Baudoin1, J. Abrahão2, S. Brah3, A. Diallo1,4, C. Sokhna1,4, N. Cassir1, B. La Scola1, F. Cadoret1 and D. Raoult1,5 1) Aix-Marseille Université, Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, UM63, CNRS 7278, IRD 198, INSERM 1095, Marseille, France, 2) Laboratório de Vírus, Departamento de Microbiologia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil, 3) Hopital National de Niamey, BP 247, Niamey, Niger, 4) Campus Commun UCAD-IRD of Hann, Route des pères Maristes, Hann Maristes, BP 1386, CP 18524, Dakar, Senegal and 5) Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia Abstract Culturomics investigates microbial diversity of the human microbiome by combining diversified culture conditions, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and 16S rRNA gene identification. The present study allowed identification of four putative new Clostridium sensu stricto species: ‘Clostridium amazonitimonense’ strain LF2T, ‘Clostridium massilidielmoense’ strain MT26T, ‘Clostridium nigeriense’ strain Marseille-P2414T and ‘Clostridium merdae’ strain Marseille-P2953T, which we describe using the concept of taxonogenomics. We describe the main characteristics of each bacterium and present their complete genome sequence and annotation. © 2017 Published by Elsevier Ltd. Keywords: ‘Clostridium amazonitimonense’, ‘Clostridium massilidielmoense’, ‘Clostridium merdae’, ‘Clostridium nigeriense’, culturomics, emerging bacteria, human microbiota, taxonogenomics Original Submission: 18 August 2017; Revised Submission: 9 November 2017; Accepted: 16 November 2017 Article published online: 22 November 2017 intestine [1,4–6].
    [Show full text]
  • Clostridium Tertium Isolated from Gas Gangrene Wound; Misidentified As Lactobacillus Spp Initially Due to Aerotolerant Feature
    ARTICLE IN PRESS Anaerobe 13 (2007) 161–165 www.elsevier.com/locate/anaerobe Short communication — Anaerobiosis: Molecular Biology, Genetics and Other Aspects Clostridium tertium isolated from gas gangrene wound; misidentified as Lactobacillus spp initially due to aerotolerant feature Shigeki Fujitania,Ã, Chengxu X. Liua, Sydney M. Finegolda, Yuli L. Songa, Glenn E. Mathisenb aInfectious Diseases Section, VA Greater Los Angeles Healthcare System, 11301 Wilshire Blvd., Los Angeles, CA 90073, USA bInfectious Disease Service, UCLA-Olive View Medical Center, 14445 Olive View Dr., Sylmar, CA 91342, USA Received 19 January 2007; received in revised form 24 February 2007; accepted 5 March 2007 Available online 12 March 2007 Abstract Clostridium tertium has been increasingly reported as a human pathogen. This organism is an aerotolerant Gram-positive rod that is often mistaken for other organisms, such as Lactobacillus or Bacillus species. We describe a case of a patient with a history of intravenous drug use presenting to UCLA-Olive View Medical Center with gas gangrene of both upper extremities. The organism was initially misidentified as a Lactobacillus species on aerobic culture plates. However, terminal spore formation was detected in this isolate on a sub- cultured anaerobic culture plate and this isolate was confirmed as C. tertium biochemically and genetically by 16S rDNA sequencing. Additional DNA cloning libraries made from the formalin-fixed specimen revealed Peptoniphilus species and an uncultured Clostridium clone, but not C. tertium. C. tertium might be a causative organism of gas-producing myonecrosis but such an association has never been described. Clinicians should be aware of the phenomenon of aerotolerance of some anaerobes and need to clarify the identification of organisms if the clinical picture does not fit the isolated organism.
    [Show full text]
  • 974-Form.Pdf
    California Association for Medical Laboratory Technology Distance Learning Program ANAEROBIC BACTERIOLOGY FOR THE CLINICAL LABORATORY by James I. Mangels, MA, CLS, MT(ASCP) Consultant Microbiology Consulting Services Santa Rosa, CA Course Number: DL-974 3.0 CE/Contact Hour Level of Difficulty: Intermediate © California Association for Medical Laboratory Technology. Permission to reprint any part of these materials, other than for credit from CAMLT, must be obtained in writing from the CAMLT Executive Office. CAMLT is approved by the California Department of Health Services as a CA CLS Accrediting Agency (#0021) and this course is is approved by ASCLS for the P.A.C.E. ® Program (#519) 1895 Mowry Ave, Suite 112 Fremont, CA 94538-1766 Phone: 510-792-4441 FAX: 510-792-3045 Notification of Distance Learning Deadline All continuing education units required to renew your license must be earned no later than the expiration date printed on your license. If some of your units are made up of Distance Learning courses, please allow yourself enough time to retake the test in the event you do not pass on the first attempt. CAMLT urges you to earn your CE units early!. CAMLT Distance Learning Course # DL-974 1 © California Association for Medical Laboratory Technology Outline A. Introduction B. What are anaerobic bacteria? Concepts of anaerobic bacteriology C. Why do we need to identify anaerobes? D. Normal indigenous anaerobic flora; the incidence of anaerobes at various body sites E. Anaerobic infections; most common anaerobic infections F. Specimen collection and transport; acceptance and rejection criteria G. Processing of clinical specimens 1. Microscopic examination 2.
    [Show full text]
  • BD Pyxis™ Inventory Connect Brochure
    PIS BD PyxisTM Inventory Connect Safe and efficient inventory management of automated and manual pharmacy stock enabling accurate inventory visibility, compliance and control Medication management faces significant challenges Drug shortages Drug waste 59% 20% of European pharmacists have of hospital inventory is seen care delayed because of discarded2 drug shortages1 Inefficiency Medication errors Over 237 half million of pharmacists’ work time is spent medication errors occur on tasks considered to be in the United Kingdom non-value adding3 each year4 When medication management relies on manual processes, lacks inventory control and involves redundant documentation procedures, it can be time-consuming, inefficient and error-prone3. Some pharmacy information systems (PIS) may have limitations in the way they handle medication inventory in non-automated storage locations adding to these inefficiencies and loss of time. Controlled and efficient inventory management The BD solution for safe, compliant, accurate and integrated inventory management is BD Pyxis™ Inventory Connect. BD Rowa™ Connected and scalable across locations BD Pyxis™ FMD Verify BD Pyxis™ Guided Pick Integrated FMD compliance Improved picking and storing efficiency Actionable analytics - enhanced order management It provides controlled and efficient inventory management, visibility and reporting in both automated and manual stock locations and will integrate to fill the existing gaps of today’s pharmacy information systems. PIS NMVS PIS BD Pyxis™ Inventory Connect BD Pyxis™
    [Show full text]
  • How Do Pesticides Influence Gut Microbiota? a Review
    International Journal of Environmental Research and Public Health Review Toxicology and Microbiota: How Do Pesticides Influence Gut Microbiota? A Review Federica Giambò 1,†, Michele Teodoro 1,† , Chiara Costa 2,* and Concettina Fenga 1 1 Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Occupational Medicine Section, University of Messina, 98125 Messina, Italy; [email protected] (F.G.); [email protected] (M.T.); [email protected] (C.F.) 2 Clinical and Experimental Medicine Department, University of Messina, 98125 Messina, Italy * Correspondence: [email protected]; Tel.: +39-090-2212052 † Equally contributed. Abstract: In recent years, new targets have been included between the health outcomes induced by pesticide exposure. The gastrointestinal tract is a key physical and biological barrier and it represents a primary site of exposure to toxic agents. Recently, the intestinal microbiota has emerged as a notable factor regulating pesticides’ toxicity. However, the specific mechanisms related to this interaction are not well known. In this review, we discuss the influence of pesticide exposure on the gut microbiota, discussing the factors influencing gut microbial diversity, and we summarize the updated literature. In conclusion, more studies are needed to clarify the host–microbial relationship concerning pesticide exposure and to define new prevention interventions, such as the identification of biomarkers of mucosal barrier function. Keywords: gut microbiota; microbial community; pesticides; occupational exposure; dysbiosis Citation: Giambò, F.; Teodoro, M.; Costa, C.; Fenga, C. Toxicology and Microbiota: How Do Pesticides Influence Gut Microbiota? A Review. 1. Introduction Int. J. Environ. Res. Public Health 2021, 18, 5510. https://doi.org/10.3390/ In recent years, the demand for food has risen significantly in relation to the world ijerph18115510 population’s increase.
    [Show full text]
  • Intra-Abdominal Granulomas Caused by Clostridium Tertium in an American Fuzzy Lop Rabbit
    Ciência Rural, SantaIntra-abdominal Maria, v.49:01, granulomas e20180777, caused by 2019 Clostridium tertium in an American http://dx.doi.org/10.1590/0103-8478cr20180777 Fuzzy Lop rabbit 1 ISSNe 1678-4596 PATHOLOGY Intra-abdominal granulomas caused by Clostridium tertium in an American Fuzzy Lop rabbit Mirella Lauria D’Elia¹ Alice Barroso Santos¹ Beatriz Novaes Telles Ribeiro¹ Renato Cesar Sacchetto Torres¹ Renato de Lima Santos¹ Rodrigo Otávio Silveira Silva¹ Anelise Carvalho Nepomuceno¹ ¹Escola de Veterinária, Universidade Federal de Minas Gerais (UFMG), Antônio Carlos Avenue, 6627, 31270-901, Belo Horizonte, MG, Brasil. E-mail: [email protected]. *Corresponding author. ABSTRACT: A 6-year-old Fuzzy Lop rabbit was referred to a veterinary hospital with a complaint of lameness. In addition to a vertebral subluxation, two radiopaque and well-defined structures were revealed by radiographic evaluation. Ultrasonographically, the masses were characterized as parenchymal structures with diffuse mineralization and formation of reverberation artifacts, suggesting presence of gas. These two structures were excised during a laparotomy and Clostridium tertium was isolated. To the best of our knowledge, this is the first report of C. tertium infection in a pet animal. Key words: Clostridia, granuloma, diagnostic imaging. Granulomas intra-abdominais causados por Clostridium tertium em um coelho American Fuzzy Lop RESUMO: Um coelho de seis anos de idade da raça Fuzzy Lop foi encaminhado a um hospital veterinário devido a uma queixa de claudicação. Além de uma subluxação vertebral, duas estruturas radiopacas e bem delimitadas foram identificadas pela avaliação radiográfica. Em um exame ultrassonográfico, as massas foram caracterizadas como formações parenquimatosas e heterogêneas, apresentando mineralização difusa e com formação de artefatos de reverberação, sugerindo a presença de gás.
    [Show full text]
  • Clostridium Tertium Bacteremia in a Non- Neutropenic Patient with Liver Cirrhosis
    Open Access Case Report DOI: 10.7759/cureus.4432 Clostridium tertium Bacteremia in a Non- neutropenic Patient with Liver Cirrhosis Mohammed Wazir 1 , Akriti G. Jain 1 , Mahum Nadeem 2 , Asad Ur Rahman 3 , George Everett 1 1. Internal Medicine, Florida Hospital, Orlando, USA 2. Internal Medicine, Basharat Hospital, Rawalpindi, PAK 3. Gastroenterology, Cleveland Clinic Florida, Weston, USA Corresponding author: Akriti G. Jain, [email protected] Abstract Clostridium tertium bacteremia is a rare condition that predominantly occurs in neutropenic patients. Clostridium tertium bacteremia, although extremely rare in non-neutropenic patients, represents the second-most common cause of bacteremia among Clostridium species. Infection with this bacteria can present variably and is usually managed with broad-spectrum antibiotics. Categories: Gastroenterology, Infectious Disease Keywords: neutropenia, clostridium tertium, cancer, cirrhosis Introduction Clostridium tertium (C. tertium) is an unusual cause of bacteremia, but when found, it is ordinarily seen in neutropenic patients. C.tertium bacteremia in non-neutropenic patients is very rare. We report a case of C. tertium bacteremia in a non-neutropenic patient with spontaneous bacterial peritonitis secondary to cirrhosis. Case Presentation A 62-year-old Caucasian male with a past medical history of hepatitis C and alcohol-induced liver cirrhosis was admitted for progressive fatigue after sustaining a fall at home. Home medications included furosemide, spironolactone, lactulose, and rifaximin. He was afebrile and vital signs were stable. He was awake, alert, and fully oriented. His physical examination was remarkable for periorbital bruising, skin abrasions, deep jaundice, dry oral mucosa, tense ascites, and mild asterixis. Computed tomography (CT) brain did not reveal evidence of intracranial bleeding.
    [Show full text]
  • BECTON, DICKINSON and COMPANY (Exact Name of Registrant As Specified in Its Charter) New Jersey 22-0760120 (State Or Other Jurisdiction of (I.R.S
    As filed with the Securities and Exchange Commission on November 24, 2010 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED SEPTEMBER 30, 2010 COMMISSION FILE NUMBER 1-4802 BECTON, DICKINSON AND COMPANY (Exact name of registrant as specified in its charter) New Jersey 22-0760120 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 1 Becton Drive 07417-1880 Franklin Lakes, New Jersey (Zip code) (Address of principal executive offices) (201) 847-6800 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Name of Each Exchange on Which Registered Common Stock, par value $1.00 New York Stock Exchange Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ¥ No n Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes n No ¥ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]